HIGHLIGHTS
- who: Cayman Williams from the National Institutes of Health (NIH), United States The University of Tokyo, Japan have published the article: Impact of CTLA-4 checkpoint antibodies on ligand binding and Transendocytosis, in the Journal: (JOURNAL)
- what: The experiments showed that both ipilimumab and tremelimumab were capable of robust blockade of CTLA-4ligand interactions.
- how: Together the above data indicated that both anti-CTLA-4 antibodies had very similar abilities to disrupt CTLA-4-ligand interactions irrespective of whether ligand or receptor was in solution.
SUMMARY
CTLA-4 is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.